Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol

Covid-19 (SARS-CoV-2) Clinical Trial

— CROWN  

Official title:

Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04476602
• Other study ID #: 20-0618
• Status: Completed
• Start date: April 27, 2020
• Est. completion date: October 15, 2020

Study information

• Verified date: July 2022
• Source: Northwell Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Descriptive report of the Northwell CROWN program for ambulatory treatment of COVID-19 (SARS-CoV-2) patients with moderate to high risk features

Description:

At the peak of the COVID-19 (SARS-CoV-2) pandemic in New York City, there was a shortage of hospital resources as well as a fear among many New Yorkers of going to the hospital. Emergency Services dead on arrival calls increased by as much as eight-fold.We created the CROWN Program, a pulmonary physician guided home-care protocol to treat ambulatory COVID-19 (SARS-CoV-2) patients with moderate to high risk features. This is a retrospective review of our CROWN program's patient characteristics, results and outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 182
• Est. completion date: October 15, 2020
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• COVID-19 (SARS-CoV-2) infection Ambulatory

Exclusion Criteria:

• Need for hospital admission

Related Conditions & MeSH terms

• COVID-19
• Covid-19 (SARS-CoV-2)

Locations

Country	Name	City	State
United States	410 Lakeville Road, Suite 107	New Hyde Park	New York

Sponsors (1)

Lead Sponsor	Collaborator
Northwell Health

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hospital Admission	admission to hospital	30 days